Teva Pharmaceuticals USA Inc. v. Synthon Pharmaceuticals, Inc.
1:14-cv-01419
📡 5G SEP • ETSI DeclaredOverview
Parties
Defendant
Teva Pharmaceutical Industries Ltd Operating Company
Represented By
2 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Teva Pharmaceuticals USA Inc. Operating Company
Represented By
9 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Plaintiff
Yeda Research and Development Co Ltd. Operating Company
Represented By
2 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Teva Neuroscience Inc Operating Company
Represented By
2 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Counter Claimant
Synthon s.r.o. Blansko NPE (Individual / Inventor)
Represented By
1 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Synthon B.V. NPE (Individual / Inventor)
Represented By
1 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Synthon Pharmaceuticals Inc. Operating Company
Represented By
6 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Amneal Pharmaceuticals LLC v. YEDA RESEARCH & DEVELOPMENT CO. LTD. et al.
Amneal Pharmaceuticals LLC v. Yeda Research & Development Co., Ltd. et al.
Mylan Pharmaceuticals Inc. et al. v. Yeda Research and Development Co. Ltd. et al.
Mylan Pharmaceuticals Inc. et al. v. Yeda Research and Development Co. Ltd. et al.
Teva Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC
Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc.
Teva Pharmaceuticals USA Inc. v. Dr Reddy's Laboratories Ltd
In Re Copaxone 40 MG Consolidated Cases
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP • ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant; CJEU Huawei v. ZTE restrictions apply.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8232250
Low frequency glatiramer acetate therapy
|
Filed: 2011-11-30
Issued: 2012-07-31
|
Active (5.0 yrs remaining)
Expires: 2031-11-30
|
|
|
US8399413
Low frequency glatiramer acetate therapy
|
Filed: 2010-08-19
Issued: 2013-03-19
|
Active (3.8 yrs remaining)
+18d PTA
Expires: 2030-09-06
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings